March 2018

Column: Are Ketamine Clinics Profiteering or Leading Innovation?

March 21, 2018

Features

The hottest subject in psychiatry right now is the clinical use of an old anesthetic (and sometimes party drug), ketamine, as the most rapidly acting and effective antidepressant the field has ever seen.

ZTlido Lowers Doses While Raising Efficacy

March 21, 2018

Clinical Pipeline

ZTlido, a lidocaine patch 1.8% developed by Scilex Pharmaceuticals, a Sorrento Therapeutics subsidiary, is attempting to redefine this type of nonopioid treatment for patients with postherpetic neuralgia.

Peer Insight: Funding and Treating Alzheimer Disease With Howard Fillit, MD

March 21, 2018

Q&A

Howard Fillit, MD, the founding executive director and chief scientific officer of the Alzheimer’s Drug Discovery Foundation, sat with MD Magazine to discuss the state of therapies for Alzheimer disease (AD), including funding-related struggles and the burden faced by physicians who treat patients with AD.

Mass General's CareZone Treats Opioid Use Disorder Where It Lives

March 21, 2018

Features

Underscoring a commitment to make health care accessible to all populations, the Kraft Center for Community Health at Massachusetts General Hospital recently launched CareZone—a mobile clinic aimed at engaging and treating those struggling with opioid use disorder and related health issues.

Are Some Risk Factors for Multiple Sclerosis Avoidable?

March 21, 2018

Features

Although the causes of MS remain unknown, a variety of factors have been linked to exacerbations and relapse—and several that have recently been associated with increased risk of onset are avoidable.